Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary

LIFECORE BIOMEDICAL, INC. DE

New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.
Bonus weighted 80% on Adjusted EBITDA and total revenue, 10% on individual objectives, 10% on company goals.
Target bonus as % of transition-period base salary: CEO Paul Josephs 100%, CFO Ryan Lake 60%, Chief Legal Tom Salus 50%.
Maximum payout capped at 200% of target level for financial goals; minimum Adjusted EBITDA threshold applies.
CY 2025 plan replaces the prior FY 2026 Bonus Plan terminated due to the fiscal year change.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.